Search results for "investments"

Article CDMOs Driving Emerging Bio/Pharma Success
CDMOs Driving Emerging Bio/Pharma Success CDMOs can claim credit for the robust growth of emerging bio/pharma financings. By Jim Miller Emerging bio/pharmaceutical companie…

Article From Darwin to Recombinant Fc Multimers
…patient safety vigilance, clarity on reimbursement and other policies, and continued innovation and investments. Of special interest to the audience was how the acquisition of BPL last year by th…

Article The Tide Stays High
Funding and investments One positive indicator for CDMOs and CROs is the robustness of venture capital investment. Venture capital money has always been more dependable than public equity, even du…

Article Modern Manufacturing Systems Key to FDA Quality Initiative
Apr 02, 2015 By Jill Wechsler Pharmaceutical Technology Volume 39, Issue 4 To ensure patient access to high quality, safe, and effective medicines, FDA spends considerable time and resou…

Article Science Focus Fuels Successful Process Development for Startups
Getting the science right helps biopharma startups overcome development and commercialization challenges. By Cynthia A. Challener sdecoret/Stock.Adobe.com Pr…

Article A Plastic Pipeline for Commercial Bioprocessing?
A Plastic Pipeline for Commercial Bioprocessing? The maturation of single-use technologies presents commercial bioprocessing options for small-volume drug products. By Rita C. Peters …

Article Patenting Prospects for Cell-Based Therapies
Nevertheless, if these investments are to be made, exclusivity—particularly patent exclusivity—will be crucial. The present patent landscape in the United States provides little comfort that these exc…

Article Contract Manufacturing Through the Years
Contract Manufacturing Through the YearsHow has the bio/pharmaceutical contract manufacturing industry evolved over the years and what does the future hoHow has the bio/pharmaceutical contract ma…

Article Biopharma Advances Demand Specialized Expertise
…hnologies? Patel (Catalent Pharma Solutions): Catalent Pharma Solutions has significant ongoing investments in enhancing our large-molecule analytical capabilities and productivity to meet and ad…

Article Monoclonal Antibodies Key to Unlocking the Biosimilars Market
“Since 2002, we have made significant investments in facilities, human resources, and technology to become a global and innovative biopharmaceutical company,” he says. Need for clear regulatory pa…

Previous PageNext Page